^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | camidanlumab tesirine (ADCT-301) (DNA replication inhibitor, CD25-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
THE ANTI-CD25 ANTIBODY-DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT-301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
Excerpt:
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma...the combinations with bendamustine and with 5-azacytidine achieved synergism in 1 out 4 cell lines (ALK+ALCL Karpas-299)....The strong single agent anti-lymphoma activity and the observed in vitro synergisms with targeted agents support the current ADCT-301 clinical development and identify potential combination partners for future clinical studies.
DOI:
https://doi.org/10.1002/hon.134_2630
